1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2019) 5:1749-68. doi: 10.1001/jamaoncol.2019.2996
2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 6:244-85. doi: 10.1097/JTO.0b013e318206a221
3. Lambe G, Durand M, Buckley A, Nicholson S, McDermott R. Adenocarcinoma of the lung: from BAC to the future. Insights Imaging (2020) 11:69. doi: 10.1186/s13244-020-00875-6
4. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol (2015) 10:1243-60. doi: 10.1097/jto.0000000000000630
5. Jiang L, Mino-Kenudson M, Roden AC, Rosell R, Molina M, Flores RM, et al. Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis. Eur J Surg Oncol (2019) 45:870-6. doi: 10.1016/j.ejso.2019.02.006
6. Kim J, Jang SJ, Choi CM, Ro JY. Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications. Adv Anat Pathol (2016) 23:330-8. doi: 10.1097/pap.0000000000000121
7. Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg (2018) 153:588-9. doi: 10.1001/jamasurg.2018.0501
8. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 10:7252-9. doi: 10.1158/1078-0432.Ccr-04-0713
9. Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, et al. Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. Eur Respir J (2015) 46:1440-50. doi: 10.1183/13993003.02358-2014
10. Glanville AR, Wilson BE. Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma. Lancet Oncol (2018) 19:e351-e8. doi: 10.1016/s1470-2045(18)30297-3
11. Zhang Y, Xie H, Zhang Z, Zhang P, Chen P, Wang X. The Characteristics and Nomogram for Primary Lung Papillary Adenocarcinoma. Open Med (2020) 15:92-102. doi: 10.1515/med-2020-0014
12. Ersek JL, Symanowski JT, Han Y, Howard A, Dumas K, Ahrens W, et al. Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis. Clin Lung Cancer (2020) 21:160-70. doi: 10.1016/j.cllc.2019.07.001
13. Arenberg D. Bronchioloalveolar carcinoma. Semin Respir Crit Care Med (2011) 32:52-61. doi: 10.1055/s-0031-1272869
14. Forest F, Patoir A, Dal-Col P, Da Cruz V, Camy F, Stachowicz ML, et al. Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old. Appl Immunohistochem Mol Morphol (2019) 27:667-71. doi: 10.1097/pai.0000000000000678
15. Borczuk AC. Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. Eur Respir Rev (2016) 25:364-71. doi: 10.1183/16000617.0089-2016
16. Moon Y, Lee KY, Sung SW, Park JK. Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis (2016) 8:169-77. doi: 10.3978/j.issn.2072-1439.2016.01.15
17. Chakraborty RK, Sharma S. Bronchoalveolar Cancer. StatPearls Publishing. 2020.
18. Zhao FN, Zhao YQ, Han LZ, Xie YS, Liu Y, Ye ZX. Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma. Clin Radiol (2019) 74:7-17. doi: 10.1016/j.crad.2018.10.001
19. Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, et al. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. J Cancer Res Clin Oncol (2016) 142:833-43. doi: 10.1007/s00432-015-2081-4
20. Song Z, Yu X, Zhang Y. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. Lung Cancer (2016) 101:16-21. doi: 10.1016/j.lungcan.2016.09.002
21. Sasada S, Miyata Y, Mimae T, Tsutani Y, Mimura T, Okada M. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma. Clin Lung Cancer (2016) 17:433-40.e1. doi: 10.1016/j.cllc.2015.11.015
22. Sasada S, Miyata Y, Mimae T, Mimura T, Okada M. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma. Ann Thorac Surg (2015) 100:2079-86. doi: 10.1016/j.athoracsur.2015.05.102
23. Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, et al. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial. J Thorac Oncol (2012) 7:1423-31. doi: 10.1097/JTO.0b013e31825ab897
24. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, et al. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer (2013) 14:351-5. doi: 10.1016/j.cllc.2012.12.004
25. Takada K, Toyokawa G, Kinoshita F, Jogo T, Kohashi K, Wakasu S, et al. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. J Cancer Res Clin Oncol (2020) 146:2639-50. doi: 10.1007/s00432-020-03250-6
26. Naso JR, Wang G, Pender A, Wong SK, Zhu J, Ho C, et al. Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. Histopathology (2020) 76:394-403. doi: 10.1111/his.13983
27. Toyokawa G, Takada K, Okamoto T, Kawanami S, Kozuma Y, Matsubara T, et al. Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. Ann Thorac Surg (2017) 103:1750-7. doi: 10.1016/j.athoracsur.2016.12.025
28. Xu Y, Zhu C, Qian W, Zheng M. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma. J Cancer Res Clin Oncol (2017) 143:181-6. doi: 10.1007/s00432-016-2255-8
29. Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, et al. What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer (2018) 118:83-9. doi: 10.1016/j.lungcan.2018.01.013
30. Suzuki S, Sakurai H, Masai K, Asakura K, Nakagawa K, Motoi N, et al. A Proposal for Definition of Minimally Invasive Adenocarcinoma of the Lung Regardless of Tumor Size. Ann Thorac Surg (2017) 104:1027-32. doi: 10.1016/j.athoracsur.2017.02.067